Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reporting times for onc year end

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Mar 01, 2024 3:07pm

190 Views

Post# 35910054

RE:RE:Reporting times for onc year end

The reasoning I prefer is that MC absolutely had to stay back to deal with new developments of some kind, not weather. One can obviously speculate as to what required his presence. It would seem likely to me that if it was of any real significanse like a signature, he would have known sooner than yesterday. However, a lot of deals are consummated on Fridays. IMHO

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders